Congress News

Immuno-Oncology – ASCO 2018

ASCO takes place in Chicago from June 1-5, 2018. During the congress, we are going to provide you with the most interesting news regarding immunotherapy in lung cancer, melanoma and gastrointestinal and genitourinary cancers here.

Supported by an unrestricted educational grant from:

This was ASCO 2018

ASCO Newsticker
Get the latest News

13. 06.

ASCO 2018 - Daily Quizzes

07. 06.

Video-Interview with Prof. Dr. Olivier Michielin about Biomarkers

07. 06.

Additive atezolizumab to chemotherapy delays progression in advanced squamous cell carcinoma of the lung

06. 06.

Scientific Knowledge Exchange on immunotherapy in lung cancer

05. 06.

Scientific Knowledge Exchange on melanoma

05. 06.

Scientific Knowledge Exchange on genitourinary cancers

05. 06.

Breakfast Brief with Prof. Dr. Olivier Michielin

04. 06.

Breakfast Brief with Univ.-Prof. Dr. Shahrokh F. Shariat

03. 06.

Pembrolizumab plus Chemotherapy as first-line treatment of metastatic squamous NSCLC

03. 06.

Pembrolizumab as Initial Treatment Works for Most Advanced Lung Cancers

03. 06.

Breakfast Brief with PD DDr. Sacha Rothschild

02. 06.

Blood Test Shows Promising Results as a Detection Tool for Early-Stage Lung Cancer

24. 05.

Upcoming ASCO 2018 Highlights

ASCO 2018 Scientific Knowledge Exchange

ASCO 2018 Immuno-Oncology

Scientific Knowledge Exchange on genitourinary cancers

ASCO 2018 Immuno-Oncology

Scientific Knowledge Exchange on melanoma

ASCO 2018 Immuno-Oncology

Scientific Knowledge Exchange on immunotherapy in lung cancer

ASCO 2018 Breakfast Brief Videos

ASCO 2018 Immuno-Oncology

Breakfast Brief with PD DDr. Sacha Rothschild

ASCO 2018 Immuno-Oncology

Breakfast Brief with Univ.-Prof. Dr. Shahrokh F. Shariat

ASCO 2018 Immuno-Oncology

Breakfast Brief with Prof. Dr. Olivier Michielin

ASCO – Daily Quiz

Which of these statements on urothelial carcinoma studies are correct?

(Select 3 answers)

A Atezolizumab is a PD-L1 inhibitor which is licenced in metastatic urothelial cancer.

B Atezolizumab given after cystectomy in operable muscle invasive transitional cell carcinoma bladder cancer is safe and associated with a meaningful pathological CR rate.

C Rogaratinib had a favorable safety profile and showed promising anti-tumor activity in urothelial cancer patients.

D Enfortumab vedotin has encouraging ORR and PFS in heavily pretreated patients with metastatic urothelial cancer.

Submit

More quizzes can be found in our News section below

News

ASCO 2018 Immuno-Oncology

ASCO 2018 - Daily Quizzes

ASCO 2018 Immuno-Oncology

Video-Interview with Prof. Dr. Olivier Michielin about Biomarkers

ASCO 2018 Immuno-Oncology

Additive atezolizumab to chemotherapy delays progression in advanced squamous cell carcinoma of the lung

The cancer immunotherapeutic agent atezolizumab appears to improve the prognosis of lung cancer patients when combined with platinum-based chemotherapy.

ASCO 2018 Immuno-Oncology

Pembrolizumab plus Chemotherapy as first-line treatment of metastatic squamous NSCLC

New Data suggest Pembrolizumab plus Chemotherapy should become a new standard-of-care for first-line treatment of metastatic squamous NSCLC, irrespective of PD-L-1 expression.

ASCO 2018 Immuno-Oncology

Pembrolizumab as Initial Treatment Works for Most Advanced Lung Cancers

The large, randomized phase III Keynote-042-trial shows that the immunotherapy pembrolizumab is a more effective initial treatment than chemotherapy for the majority of patients.